NovoLog® is designed to mimic the normal physiologic insulin profile1

NovoLog® (insulin aspart [rDNA origin] injection) is a rapid-acting insulin analog that is engineered for mealtime use. Compared with subcutaneously administered regular human insulin, NovoLog® has a faster onset of action, an earlier and higher peak concentration, and a shorter duration of action. NovoLog® can help control mealtime glucose spikes, without the “long tail” of regular human insulin.2-4

NovoLog® pharmacokinetics2

Mean free serum insulin concentrations collected in 22 patients with type 1 diabetes for up to 6 hours following a single dose of NovoLog® injected before a meal vs regular human insulin injected immediately before a meal.2

Adapted from Lindholm et al. 1999.2

NovoLog® has a more rapid onset and shorter duration of action than regular human insulin

Onset of action:
  • 10 to 20 minutes for NovoLog® vs 30 minutes for regular human insulin
Peak concentration
  • 40 to 50 minutes for NovoLog® vs 80-120 minutes for regular human insulin
Duration of action
  • 3 to 5 hours for NovoLog® vs up to 8 hours for regular human insulin